Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for COMT    
Back Search Methods Disclaimer Credits
 Gene: COMT   Entrez Gene    View on AlzGene   View on MSGene   View on PDGene
 Protein: catechol-O-methyltransferase   ProteinLink
 Chromosome: 22   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 21 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Anttila, 2004
 Overlaps with
Illi, 2003		 CL  1  (detail)  94
(51%)		IV--98
(-)		-n.a.
Costas, 2010
 Spain (Valencia) CL  1  (detail)  371
(35%)		IV--417
(37%)		-Negative
Costas, 2010
 Spain (Santiago de Compostela) CL  1  (detail)  391
(33%)		IV--625
(47%)		-Positive
Daniels, 1996
 UK, Ireland CL  1  (detail)  78
(35%)		IIIR-44.3 + 13.5
(-)		78
(35%)		44 + 12.2
(-)		Negative
de Chaldee, 1999
 France CL  4  (detail)  143
(29%)		IIIR-40 + 12.9
(-)		191
(44%)		49 + 10
(-)		Positive
Dutt, 2009
 UK, Ireland CL  1  (detail)  83
(-)		IV--57
(-)		-Negative
Egan, 2001
 USA (CBDB) CL  1  (detail)  175
(21%)		IV-36.1 + 8.5
(18-60)		55
(58%)		33.9 + 9.2
(18-60)		Positive
Eisenberg, 2009
 USA CL  1  (detail)  25
(24%)		IV-27.5 + 6.2
(18-43)		47
(30%)		28.7 + 7.5
(20-50)		n.a.
Funke, 2005
 USA CL  4  (detail)  196
(-)		IV--467
(52%)		39.3
(-)		Positive
Galderisi, 2005
 Italy CL  1  (detail)  106
(28%)		IV--111
(-)		-Negative
Gallinat, 2003
 Germany CL  1  (detail)  49
(24%)		IV-32.8 + 9.3
(-)		170
(50%)		43.9 + 14.9
(-)		Negative
Goghari, 2007
 USA CL  1  (detail)  41
(22%)		IV-45.2 + 10.7
(-)		20
(115%)		48.1 + 15.1
(-)		Negative
Goldberg, 2003
 Overlaps with
Egan, 2001		 CL  1  (detail)  74
(41%)		IV-37 + 8
(-)		68
(59%)		-n.a.
Golimbet, 2006
 Russia CL  1  (detail)  124
(49%)		1023.9 + 8.3
(-)		34.5 + 12.9
(-)		116
(58%)		32.2 + 12.9
(-)		Negative
Haraldsson, 2008
 Iceland CL  1  (detail)  112
(28%)		U-41 + 9.9
(-)		97
(36%)		40.6 + 9.3
(-)		Negative
Haraldsson, 2009
 Overlaps with
Haraldsson, 2008		 CL  1  (detail)  110
(28%)		M-41 + 10
(-)		96
(36%)		41 + 9
(-)		n.a.
Herken, 2001
 Overlaps with
Herken, 2003a		 CL  1  (detail)  129
(33%)		IV-34.3 + 9.9
(-)		65
(34%)		30.7 + 6.3
(-)		n.a.
Herken, 2003a
 Turkey CL  1  (detail)  143
(35%)		IV-32.3 + 9.1
(-)		79
(-)		-Negative
Ho, 2005
 USA CL  1  (detail)  159
(26%)		M-26.5 + 7.3
(-)		84
(60%)		27 + 7
(-)		Negative
Hoenicka, 2009
 Spain CL  2  (detail)  337
(33%)		IV22.8 + 6.3
(-)		-285
(40%)		-Positive
Hoenicka, 2010
 Overlaps with
Hoenicka, 2009		 CL  1  (detail)  337
(33%)		IV--364
(53%)		-n.a.
Hoogendoorn, 2005
 Netherlands CL  1  (detail)  208
(-)		IV--288
(-)		-Negative
Horowitz, 2005
 Israel (I) CL  5  (detail)  190
(41%)		U--188
(41%)		-Negative
Horowitz, 2005
 Israel (II) CL  3  (detail)  535
(38%)		U--567
(39%)		-Negative
Horowitz, 2005
 Overlaps with
Horowitz, 2005 Israel (II)		 CL  3  (detail)  190
(41%)		U--188
(41%)		-n.a.
Illi, 2003
 Finland CL  1  (detail)  94
(51%)		IV--94
(50%)		-Negative
Jones, 2001
 Overlaps with
Norton, 2002		 CL  1  (detail)  180
(24%)		IV--173
(-)		-n.a.
Joober, 2002
 Canada CL  1  (detail)  104
(-)		IV--96
(-)		-Negative
Karayiorgou, 1998
 USA CL  5  (detail)  157
(32%)		IIIR--129
(-)		-Negative
Kotler, 1999
 Israel CL  1  (detail)  92
(37%)		10--415
(62%)		28 + 15
(-)		Negative
Krabbendam, 2006
 Spain CL  1  (detail)  23
(30%)		IV-36 + 10.5
(-)		21
(57%)		38.3 + 15.6
(-)		Negative
Martorell, 2007
 Spain CL  11  (detail)  585
(34%)		IV-48.8 + 17.5
(-)		615
(48%)		43.1 + 15.3
(-)		Negative
Mas, 2009
 Spain CL  4  (detail)  159
(-)		IV--373
(54%)		51.9 + 19
(-)		Negative
Muntjewerff, 2007
 Netherlands CL  1  (detail)  252
(27%)		IV-41 + 14
(-)		405
(59%)		51 + 13
(-)		Negative
Nicodemus, 2006
 Germany CL  3  (detail)  501
(35%)		IV--627
(52%)		-Positive
Nicodemus, 2006
 USA CL  3  (detail)  296
(21%)		IV--370
(51%)		-Positive
Nieratschker, 2010
 Overlaps with
Strohmaier, 2010		 CL  13  (detail)  631
(45%)		IV-38.5 + 11.7
(-)		776
(43%)		45.5 + 13.5
(-)		n.a.
Norton, 2002
 Overlaps with
Williams, 2005		 CL  1  (detail)  346
(28%)		IV-46 + 13
(-)		334
(29%)		43 + 12
(-)		n.a.
Norton, 2002
 UK CL  1  (detail)  346
(28%)		IV-46 + 13
(-)		334
(29%)		43 + 12
(-)		Negative
Pal, 2009
 Croatia CL  11  (detail)  103
(42%)		10-43.6 + 10.6
(23-74)		131
(-)		50.3 + 7.5
(30-74)		Positive
Pomarol-Clotet, 2010
 Overlaps with
Hoenicka, 2009		 CL  1  (detail)  42
(26%)		IV20
(-)		39.8 + 10
(23-63)		31
(35%)		35.8 + 14.2
(20-58)		n.a.
Poyurovsky, 2005
 Israel CL  1  (detail)  113
(28%)		IV--171
(56%)		-Negative
Prata, 2009a
 UK CL  1  (detail)  42
(17%)		IV-35.5 + 11.4
(-)		48
(52%)		34.1 + 10.7
(-)		Positive
Prata, 2009b
 Overlaps with
Prata, 2009a		 CL  1  (detail)  41
(-)		IV--44
(-)		-n.a.
Rosa, 2010
 Overlaps with
Sanders, 2008 (USA-NIMH)		 CL  1  (detail)  67
(21%)		IV-34 + 9.8
(-)		168
(57%)		36 + 10.8
(-)		n.a.
Rujescu, 2003
 Germany CL  1  (detail)  28
(-)		U--328
(55%)		46 + 15
(19-79)		Negative
Rybakowski, 2002
 Poland CL  1  (detail)  117
(37%)		M-30
(18-63)		60
(52%)		27
(22-60)		Negative
Sanders, 2008
 USA, Australia CL  29  (detail)  1870
(31%)		IV--2002
(53%)		-Negative
Sazci, 2004
 Turkey CL  1  (detail)  297
(43%)		IV-41.2 + 9.4
(-)		341
(44%)		40.9 + 8.1
(-)		Positive
Shaikh, 2010
 Overlaps with
Dutt, 2009		 CL  1  (detail)  70
(-)		IV--204
(63%)		40.1 + 13.2
(18-65)		n.a.
Shifman, 2002
 Israel (I) CL  1  (detail)  720
(36%)		IV--2970
(24%)		-Positive
Shifman, 2002
 Israel (II) CL  1  (detail)  724
(36%)		IV--4899
(28%)		-Positive
Shifman, 2002
 Israel (III) CL  1  (detail)  714
(35%)		IV--2849
(24%)		-Positive
Straub, 2007
 Overlaps with
Egan, 2001		 CL  2  (detail)  309
(21%)		IV--317
(49%)		-n.a.
Strohmaier, 2010
 Germany CL  14  (detail)  634
(45%)		IV-38.5 + 11.7
(-)		776
(43%)		45.5 + 13.5
(-)		Negative
Strous, 1997
 USA CL  1  (detail)  54
(-)		IIIR--87
(-)		-Negative
Szoke, 2006
 France CL  1  (detail)  66
(35%)		IV-34.1 + 8.9
(18-60)		50
(48%)		42.2 + 12.9
(18-60)		Negative
Talkowski, 2008
 USA CL  15  (detail)  478
(-)		IV--501
(-)		-Positive
Talkowski, 2008
 Overlaps with
Talkowski, 2008		 CL  5  (detail)  328
(-)		IV--501
(-)		-n.a.
Williams, 2005
 UK CL  3  (detail)  709
(-)		IV--710
(69%)		-Negative
Wirgenes, 2010
 Norway CL  15  (detail)  171
(46%)		IV-33.7 + 9.6
(-)		340
(50%)		34.9 + 10.1
(-)		Positive
Wonodi, 2006
 Overlaps with
Wonodi, 2003		 CL  1  (detail)  86
(34%)		IV--50
(44%)		-n.a.
Zumarraga, 2010
 Spain CL  1  (detail)  44
(48%)		IV-35 + 11
(-)		96
(63%)		44 + 10
(19-65)		Negative
 Asian
Arinami, 2001
 Japan CL  1  (detail)  300
(44%)		IIIR22.6
(12-39)		44.3
(19-78)		300
(45%)		47.8
(29-75)		Negative
Chen, 1996
 Overlaps with
Chen, 1999		 CL  1  (detail)  177
(46%)		IIIR-47
(-)		99
(45%)		45
(-)		n.a.
Chen, 1997
 Overlaps with
Chen, 1999		 CL  1  (detail)  177
(46%)		IIIR-47
(-)		99
(45%)		45
(-)		n.a.
Chen, 1997
 Taiwan CL  1  (detail)  177
(46%)		IIIR-47
(-)		99
(45%)		45
(-)		Negative
Chen, 1999
 Taiwan CL  4  (detail)  177
(46%)		IV-47 + 6
(-)		99
(45%)		45 + 5
(-)		Negative
Chien, 2009
 Taiwan CL  3  (detail)  124
(43%)		IV21.9 + 5.5
(-)		37.5 + 6.8
(-)		112
(62%)		31.8 + 7.6
(-)		Negative
Fan, 2005
 China CL  1  (detail)  862
(43%)		IIIR-39.8 + 12
(-)		928
(40%)		38.3 + 11.7
(-)		Negative
Han, 2004
 Korea CL  1  (detail)  168
(0%)		IV--158
(0%)		-Negative
Han, 2006
 Korea CL  1  (detail)  132
(0%)		IV--80
(0%)		-Negative
Inada, 2003
 Japan CL  1  (detail)  100
(-)		IIIR--201
(-)		-Negative
Iwata, 2003
 Japan CL  1  (detail)  51
(57%)		IV13.5 + 1.7
(9-16)		20 + 7
(-)		148
(56%)		21 + 7
(-)		Negative
Joo, 2005
 Korea CL  1  (detail)  239
(38%)		IV-33.3 + 8.1
(-)		248
(43%)		23.9 + 6.7
(-)		Negative
Kang, 2010
 China CL  1  (detail)  287
(44%)		IV24.3
(-)		27.8 + 3.1
(-)		84
(54%)		26.6 + 2.9
(-)		Negative
Kim, 2008
 Korea CL  1  (detail)  165
(42%)		IV24.5 + 6.9
(-)		38.4 + 10.1
(-)		415
(40%)		24.5 + 5.7
(19-57)		Negative
Lee, 2005
 Korea CL  5  (detail)  320
(52%)		IV-32.6 + 10
(-)		379
(51%)		40.1 + 14
(-)		Positive
Liou, 2001
 Taiwan CL  1  (detail)  198
(53%)		IV-37.8 + 12.1
(-)		188
(48%)		38.6 + 16.6
(-)		Negative
Numata, 2006
 Japan CL  1  (detail)  159
(28%)		IV25.9 + 8.3
(-)		53.9 + 12.8
(-)		317
(-)		-Negative
Nunokawa, 2007
 Japan CL  5  (detail)  399
(47%)		IV23.1 + 7.2
(-)		40.6 + 14.7
(-)		440
(48%)		38 + 10.4
(-)		Negative
Ohmori, 1998
 Japan CL  1  (detail)  150
(57%)		IV-54 + 11.5
(-)		150
(50%)		55 + 6.8
(-)		Positive
Ohnishi, 2006
 Japan CL  1  (detail)  47
(-)		IV--76
(-)		-Negative
Park, 2002
 Korea CL  1  (detail)  103
(39%)		IV-42.1 + 8.1
(-)		103
(-)		-Positive
Park, 2009
 Korea CL  6  (detail)  354
(50%)		IV-44 + 9.3
(23-76)		396
(43%)		54.6 + 9.3
(28-80)		Positive
Sun, 2005
 China CL  2  (detail)  82
(-)		10--108
(-)		-Positive
Wang, 2009
 China CL  14  (detail)  540
(45%)		IV--660
(46%)		-Positive
Yu, 2007
 China CL  3  (detail)  241
(46%)		IV--290
(45%)		-Negative
 Other/Mixed
Ehrlich, 2009
 USA CL  1  (detail)  98
(26%)		IV-35.1 + 10.8
(-)		114
(39%)		32.1 + 11.1
(-)		n.a.
Gupta, 2009
 India CL  7  (detail)  254
(39%)		IV-29.2 + 7.6
(-)		225
(62%)		86 + 31
(-)		Positive
Kremer, 2003
 Palestine CL  1  (detail)  276
(69%)		IV21 + 4.8
(-)		34.8 + 13.6
(-)		77
(69%)		39.5 + 15.5
(-)		Positive
Roffman, 2008
 Overlaps with
Ehrlich, 2009		 CL  1  (detail)  79
(-)		IV--75
(-)		-n.a.
Semwal, 2002
 India CL  1  (detail)  536
(44%)		IV-22.8 + 7
(-)		936
(47%)		32.9 + 12.7
(-)		Negative
Srivastava, 2010
 Overlaps with
Semwal, 2002		 CL  5  (detail)  215
(48%)		IV21.4 + 6.1
(-)		29.3 + 8.9
(-)		215
(40%)		34.6 + 12.4
(-)		Positive
Thaker, 2004
 USA CL  1  (detail)  62
(-)		U-41 + 10
(-)		53
(-)		41 + 15
(-)		Negative
Wonodi, 2003
 USA CL  1  (detail)  96
(32%)		IV-43.2 + 10.7
(-)		79
(43%)		42.5 + 15.9
(-)		Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Chen, 2004
 Ireland (ISHDSF)  3  (detail)  267515
(-)		IIIR--822
(-)		-Positive
Egan, 2001
 Overlaps with
Egan, 2001 (CC)		  1  (detail)   175
(-)		IV--219
(-)		-Positive
Fallin, 2005
 USA  7  (detail)  263274
(26%)		IV19.5 + 4.5
(-)		-548
(50%)		-Negative
Glaser, 2006
 Bulgaria  1  (detail)  488488
(46%)		M-33 + 8
(-)		976
(50%)		59.5 + 9
(-)		Negative
Goldberg, 2003
 Overlaps with
Egan, 2001 (CC)		  1  (detail)  74-IV----n.a.
Handoko, 2005
 Australia  4  (detail)  50107
(-)		IV----Positive
McClay, 2006
 Overlaps with
Chen, 2004		  1  (detail)  268-U----n.a.
Nieratschker, 2010
 Overlaps with
Strohmaier, 2010		  13  (detail)  207207
(37%)		IV-29.6 + 7.5
(-)		--n.a.
Shaikh, 2010
 Overlaps with
Dutt, 2009		  1  (detail)   138
(40%)		IV-40.8 + 11.8
(21-65)		109
(53%)		45.9 + 12.8
(19-65)		Negative
Straub, 2007
 Overlaps with
Egan, 2001		  2  (detail)  269309
(21%)		IV--372
(58%)		-n.a.
Strohmaier, 2010
 Germany  14  (detail)  180-IV----Negative
Talkowski, 2008
 Bulgaria  16  (detail)  659659
(50%)		IV--1318
(50%)		-Negative
Talkowski, 2008
 USA  6  (detail)  150150
(50%)		IV--300
(50%)		-Positive
Wei, 1999
 UK  2  (detail)  4949
(41%)		U--98
(50%)		-Negative
Williams, 2005
 Bulgaria  3  (detail)  488488
(-)		IV--976
(50%)		-Negative
 Asian
Chien, 2009
 Taiwan  3  (detail)  83-IV22.4 + 6.3
(-)		---Positive
Fan, 2002
 China  5  (detail)  166166
(39%)		IIIR--332
(50%)		-Negative
Li, 1996
 China  1  (detail)  178178
(36%)		IIIR-26.7 + 6.6
(15-49)		356
(50%)		-Trend
Li, 2000
 China  7  (detail)  198198
(39%)		M-26.7 + 6.7
(15-49)		396
(50%)		-Positive
Liao, 2009
 Taiwan  3  (detail)  212251
(-)		IV--429
(-)		-Positive
Semwal, 2001
 Overlaps with
Semwal, 2002		  1  (detail)  179179
(42%)		IV22.1 + 6.3
(-)		-358
(50%)		-n.a.
Tsai, 2006
 China  1  (detail)  220220
(41%)		IV-30.3 + 8.2
(-)		440
(50%)		-Negative
 Other/Mixed
Kremer, 2003
 Overlaps with
Kremer, 2003		  1  (detail)  248276
(69%)		IV21 + 4.8
(-)		34.8 + 13.6
(-)		--n.a.
Kunugi, 1997
 UK, Japan  2  (detail)  2276
(-)		U----Negative
Liu, 2002a
 Overlaps with
Liu, 2002b USA (II)		  1  (detail)  2626
(-)		IV10.1 + 1.8
(-)		-52
(50%)		-n.a.
Liu, 2002a
 USA (I)  2  (detail)  107107
(-)		IV--214
(50%)		-Negative
Liu, 2002a
 USA (II)  2  (detail)  2626
(-)		IV10.1 + 1.8
(-)		-52
(50%)		-Negative
Liu, 2002a
 Overlaps with
Liu, 2002b USA (I)		  1  (detail)  107107
(-)		IV--214
(50%)		-n.a.
Liu, 2002b
 USA (I)  1  (detail)  107107
(-)		IV--214
(50%)		-Positive
Liu, 2002b
 USA (II)  1  (detail)  2626
(-)		IV10.1 + 1.8
(-)		-52
(50%)		-Positive
Sanders, 2005
 USA  5  (detail)  136136
(48%)		IIIR20
(5-45)		-510
(-)		-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2023 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright